Last reviewed · How we verify
NCT03244215
The Recurrence Study
NA trial testing Corneal Confocal Imaging in Acute Stroke in 300 participants. Status unknown.
17 February 2018
Quick facts
| Lead sponsor | Hamad Medical Corporation |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 300 |
| Start date | 17 February 2016 |
| Primary completion | 17 February 2018 |
| Estimated completion | 17 May 2018 |
| Sites | 1 location across Qatar |
Drugs / interventions tested
- Corneal Confocal Imaging
- Magnetic resonance Imaging
- Blood sample — full drug profile →
Conditions studied
- Acute Stroke — all drugs for Acute Stroke →
- Transient Ischemic Attack — all drugs for Transient Ischemic Attack →
Sponsor
Hamad Medical Corporation — full company profile →
Who can join
18 and older, any sex, with Acute Stroke or Transient Ischemic Attack. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primarily goal of the research is to better understand progression of disease in patients who present with an acute stroke to the Hamad General Hospital (HGH) stroke and Transient Ischemic Attack (TIA) clinic. The investigators are specifically interested in patients who have diabetes and have a stroke. The patients enrolled into the research will have detailed clinical evaluation and their imaging studies (MRI and Doppler) will be reviewed. After informed consent, subjects will be examined in the stroke Ward /TIA clinic upon recruitment, and later at less than 48 hours of recruitment (blood extraction and urine samples) and for follow up visits at 1 month+/-7 days (clinical evaluation and to extract blood and urine samples), at 3 months (telephonic conversation only) and at 1 year (clinical and repeat MRI brain). During the initial visit at the ward the investigators will collect serum and plasma for proteomic and metabolomic studies. These will be repeated at less than 48 hours and at 1 month+/-7 days. Investigators will test the effects of risk factors such as diabetes/stroke on the endothelial procoagulant and inflammatory state at onset and evaluate if best medical control leads to improvement in such markers.The repeated studies will determine if better management and presence of certain blood biomarkers can predict or translate to slower progression of disease and correlate it with clinical status.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03244215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Stroke
Currently open trials in the same condition.
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
- NCT07355881 — mSOAR and Early Mortality in Acute Stroke · recruiting
- NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
- NCT07167550 — The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke · Phase 3 · recruiting
Other Hamad Medical Corporation trials
Trials by the same sponsor.
- NCT07333209 — Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia · NA · recruiting
- NCT07270939 — Optimizing Enteral Nutrition Regimen for Critically Ill Patients · NA · not yet recruiting
- NCT07307508 — Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Ra · NA · recruiting
- NCT06622577 — The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric · NA · not yet recruiting
- NCT06887855 — Enhancing Post-Stroke Dysphagia Rehabilitation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03244215 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hamad Medical Corporation
- Last refreshed: 9 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03244215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing